Bioporto A/S
CSE:BIOPOR

Watchlist Manager
Bioporto A/S Logo
Bioporto A/S
CSE:BIOPOR
Watchlist
Price: 1.624 DKK -2.4% Market Closed
Market Cap: 697.8m DKK
Have any thoughts about
Bioporto A/S?
Write Note

Gross Margin
Bioporto A/S

71.1%
Current
65%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
71.1%
=
Gross Profit
24.1m
/
Revenue
33.8m

Gross Margin Across Competitors

Country Company Market Cap Gross
Margin
DK
Bioporto A/S
CSE:BIOPOR
697.8m DKK
71%
FR
Pharnext SCA
OTC:PNEXF
6T USD
0%
US
Abbvie Inc
NYSE:ABBV
312.7B USD
67%
US
Amgen Inc
NASDAQ:AMGN
158.3B USD
60%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
116.2B USD
86%
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD
78%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
AU
CSL Ltd
ASX:CSL
133.6B AUD
52%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
81.3B USD
87%
US
Seagen Inc
F:SGT
39.3B EUR
75%
NL
argenx SE
XBRU:ARGX
34.8B EUR
89%
Country DK
Market Cap 697.8m DKK
Gross Margin
71%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 312.7B USD
Gross Margin
67%
Country US
Market Cap 158.3B USD
Gross Margin
60%
Country US
Market Cap 116.2B USD
Gross Margin
86%
Country US
Market Cap 112.4B USD
Gross Margin
78%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 133.6B AUD
Gross Margin
52%
Country US
Market Cap 81.3B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 34.8B EUR
Gross Margin
89%
No Stocks Found

Bioporto A/S
Glance View

Market Cap
697.8m DKK
Industry
Biotechnology

Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

BIOPOR Intrinsic Value
1.257 DKK
Overvaluation 23%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
71.1%
=
Gross Profit
24.1m
/
Revenue
33.8m
What is the Gross Margin of Bioporto A/S?

Based on Bioporto A/S's most recent financial statements, the company has Gross Margin of 71.1%.